Article
Officials with the FDA have expanded the approval of Kaleo’s epinephrine injection, USP (Auvi-Q) to include the treatment of life-threatening allergic reactions in infants and small children.
Officials with the FDA have expanded the approval of Kaleo’s epinephrine injection, USP (Auvi-Q) to include the treatment of life-threatening allergic reactions in infants and small children.1
With this approval, Auvi-Q 0.1 mg can be used to treat anaphylaxis in infants and small children weighing 16.5 to 33 pounds, who are at risk for or have a history of serious allergic reactions.
The new EAI also includes an electronic voice instruction system as well as visual cues to help guide users step-by-step through the administration.
According to a study published in the Allergy, Asthma, & Clinical Immunology, 43% of children weighing 16.5-33 pounds treated with a 0.15 mg EAI with a standard 12.7 mm needle length are at risk of the needle striking the bone.2 The 0.1-mg dose EAI has a shorter needle length, designed for use with infants and small children, and a lower dose of epinephrine than the current 0.15 mg and 0.3 EAIs.
According to the company’s press release, there was a 129.8% increase in emergency room visits for anaphylaxis among children aged 4 years and younger between 2005 and 2014.
Auvi-Q 0.1 mg is projected to be available to patients in the first half of 2018.
References
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.